TITLE

Big pharma braces for wave of patent losses

AUTHOR(S)
Mirasol, Feliza
PUB. DATE
January 2008
SOURCE
ICIS Chemical Business;1/7/2008, Vol. 273 Issue 1, p24
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that court challenges to pharmaceutical patents have been all the rage lately in the U.S., so pharmaceutical majors are trying to improve their defenses amid a slew of patent losses and new generics. With the status quo shifting from the blockbuster-based business model to more specialized, targeted therapeutics, the chances of big pharmaceutical firms triumphing with one or two new multibillion-dollar drugs are few and far between in the foreseeable future.
ACCESSION #
28686869

 

Related Articles

  • THAILAND: Sector Outlook - Pharmaceuticals.  // Asia Monitor: South East Asia Monitor Volume 1;Nov2003, Vol. 14 Issue 11, p3 

    This article overviews pharmaceutical industry in Thailand as of November 1, 2003. As Thailand has recovered from the Asian economic crisis, so has its pharmaceutical sector. However, market growth has been visible mostly only in local currency terms, with growth in U.S. dollar terms negligible...

  • Patent expirations spell big changes for generic industry. Cassell, Dana K. // Drug Topics;8/6/2001 Supplement, Vol. 145 Issue 15, p9 

    Focuses on the increase of patent expirations among pharmaceutical industries in the United States. List of top eight drugs going off patent before December 2005; Delay of patent expiration due to court trials; Plan of an educational campaign on safety and efficacy of generic drugs.

  • Rational Decisions. Garvey, John; Morency, Michel // Bio-IT World;Jun2004, Vol. 3 Issue 6, p94 

    Focuses on the patent regulation for discovered genes and computationally guided rational drug designs (CGRDD). Impact of the changes in patent laws on genes and CGRDD patents; Failure of genomics companies to obtain adequate legal protection for their genetic discovery; Advantages of patents...

  • Attack Mounts on Drug Prices. Wechsler, Jill // Pharmaceutical Technology North America;Sep2002, Vol. 26 Issue 9, p16 

    Reports on the enactment of a bill designed to make prescription drugs more affordable in the U.S. Revision of a patent law to bring less expensive genetic drugs to market; Support of the pharmaceutical industry on the bill; Adoption of a generic drug reform legislation. INSETS: Bush backs...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Big Pharma's Bad Week in Washington. Mullin, Rick // Chemical Week;8/7/2002, Vol. 164 Issue 31, p30 

    Reports on the approval of the Greater Access to Affordable Pharmaceuticals bill aimed at closing loopholes in the 1984 Hatch-Waxman drug patent law in the U.S. Cancellation of a plan to provide prescription drug benefits under Medicare; Opposition of the Pharmaceutical Research and...

  • Generic Pharmaceuticals: IP's Fiercest Litigation Arena. Andersen, Steven // Corporate Legal Times;Nov2003, Vol. 13 Issue 144, p28 

    Focuses on the complications in the generic drug application for patent rights by pharmaceutical companies in the U.S. Employment of strategy to extend the patent life of their products; Impact of the emergence of generic drugs on the pharmaceutical companies; Overview of the process of the...

  • Innovator Exclusivity Options.  // Drug Discovery & Development;Feb2004, Vol. 7 Issue 2, p13 

    Reports on the marketing exclusivity and patent protection on the success of U.S. pharmaceutical companies. Provisions of the non-patent exclusivity; Financial benefits of patent protection; Legislation that enacted important market incentives for pharmaceutical innovators. INSET: At a Glance.

  • Novelty: new products and processes. French, Hayley // Nature Reviews Drug Discovery;Jun2004, Vol. 3 Issue 6, p469 

    It is a central tenet of patent law that anything that is not new is unpatentable. This follows from the principle that patents cannot be extended to material that is already in the public domain. In the first of two pieces on novelty, this article looks at what novelty means with respect to new...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics